Q2 2025 Earnings Call Transcript August 4, 2025 Axsome Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.92 ...

Analysts expect Axsome Therapeutics to report an earnings per share (EPS) of $-1.06. Anticipation surrounds Axsome ...

Axsome Therapeutics stock has climbed nearly 45% this year, including Tuesday's big drop. Shares rank sixth on the IBD 50 list of elite growth stocks and have a strong IBD Digital Relative ...

--Axsome Therapeutics, Inc., a biopharmaceutical company leading a new era in the treatment of central nervous system disorders, today announced it will report its financial results for the second ...

In the assessment of 12-month price targets, analysts unveil insights for Axsome Therapeutics, presenting an average target ...

Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $139.13. The firm has a market cap of $5.17 billion, a price-to-earnings ratio of -17.54 and a beta of 0.46.

Axsome Therapeutics (AXSM 11.52%) may have what it takes to escape this less-than-ideal fate. Since going public in 2015, Axsome's shares have appreciated by a jaw-dropping 876%.

Axsome Therapeutics (AXSM) has received formal pre-New Drug Application meeting minutes from the U.S. Food and Drug Administration supporting a supplemental NDA submission for AXS-05 in Alzheimer ...

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited ...

Axsome's new products have blockbuster potential.Some stocks soar overnight. But in most cases, you'll have a better chance of winning in the stock market if you buy and hold on for at least five ...

Axsome Contact: Mark Jacobson Senior Vice President, Operations Axsome Therapeutics, Inc.200 Broadway, 3rd Floor New York, NY 10038 Tel: 212-332-3243 Email: mjacobson@axsome.com www.axsome.com ...